23andMe’s fall from fame ends in Regeneron takeover
BBC - 19-May-2025Regeneron buys 23andMe for $256M, pledges to protect user data and boost drug discovery
Regeneron Pharmaceuticals
Biotechnology company
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, it branched out into the study of both cytokine and tyrosine kinase receptors.
Visit website: https://www.regeneron.com/
Details last updated 05-May-2020
Regeneron Pharmaceuticals News
Gene therapy restores hearing in children with rare deafness
FierceBiotech - 24-Feb-2025Regeneron’s DB-OTO offers new hope for genetic hearing loss
Genetic profiling conducted by the mexico city prospective study highlights the value of genetic studies in diverse populations
Oxford Population Health - 11-Oct-2023Study reveals new insights into obesity, diabetes, and genetic diversity
Unity Biotechnology's diabetic macular edema senolytic treatment shows promise at 48-week endpoint
FierceBiotech - 24-Apr-2023Corporate shift towards ophthalmology puts senolytics head-to-head against existing treatments
New CRISPR gene-editing drug for a rare protein-misfolding disorder
pharmaphorum - 28-Jun-2021Phase 1 trial reports, single dose of the drug cuts protein levels by 87% in ATTR amyloidosis
Display all news
People at Regeneron Pharmaceuticals
